Baolingbao Biology Co Ltd (SHE:002286) — Market Cap & Net Worth
Market Cap & Net Worth: Baolingbao Biology Co Ltd (002286)
Baolingbao Biology Co Ltd (SHE:002286) has a market capitalization of $426.47 Million (CN¥2.91 Billion) as of September 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #13117 globally and #3872 in its home market, demonstrating a -8.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Baolingbao Biology Co Ltd's stock price CN¥7.67 by its total outstanding shares 379977380 (379.98 Million). Also see 002286 asset base for a full breakdown of the balance sheet.
Baolingbao Biology Co Ltd Market Cap History: 2015 to 2026
Baolingbao Biology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $756.41 Million to $426.47 Million (-5.11% CAGR). Also see how efficiently does Baolingbao Biology Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Baolingbao Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Baolingbao Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002286 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.18x
Baolingbao Biology Co Ltd's market cap is 0.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.30x
Baolingbao Biology Co Ltd's market cap is 3.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $879.04 Million | $1.38 Billion | $49.34 Million | 0.64x | 17.82x |
| 2017 | $513.33 Million | $1.59 Billion | $49.62 Million | 0.32x | 10.34x |
| 2018 | $290.71 Million | $1.73 Billion | $42.95 Million | 0.17x | 6.77x |
| 2019 | $322.21 Million | $1.81 Billion | $35.23 Million | 0.18x | 9.14x |
| 2020 | $612.39 Million | $2.05 Billion | $49.86 Million | 0.30x | 12.28x |
| 2021 | $730.14 Million | $2.76 Billion | $201.58 Million | 0.26x | 3.62x |
| 2022 | $493.65 Million | $2.71 Billion | $133.17 Million | 0.18x | 3.71x |
| 2023 | $445.29 Million | $2.52 Billion | $53.97 Million | 0.18x | 8.25x |
| 2024 | $410.35 Million | $2.40 Billion | $111.16 Million | 0.17x | 3.69x |
| 2025 | $497.09 Million | $2.75 Billion | $150.63 Million | 0.18x | 3.30x |
Competitor Companies of 002286 by Market Capitalization
Companies near Baolingbao Biology Co Ltd in the global market cap rankings as of September 17, 2026. Review 002286 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Baolingbao Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Baolingbao Biology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Baolingbao Biology Co Ltd's market cap moved from $756.41 Million to $ 426.47 Million, with a yearly change of -5.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥426.47 Million | -14.21% |
| 2025 | CN¥497.09 Million | +21.14% |
| 2024 | CN¥410.35 Million | -7.85% |
| 2023 | CN¥445.29 Million | -9.80% |
| 2022 | CN¥493.65 Million | -32.39% |
| 2021 | CN¥730.14 Million | +19.23% |
| 2020 | CN¥612.39 Million | +90.06% |
| 2019 | CN¥322.21 Million | +10.83% |
| 2018 | CN¥290.71 Million | -43.37% |
| 2017 | CN¥513.33 Million | -41.60% |
| 2016 | CN¥879.04 Million | +16.21% |
| 2015 | CN¥756.41 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Baolingbao Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $426.47 Million USD |
| MoneyControl | $426.47 Million USD |
| MarketWatch | $426.47 Million USD |
| marketcap.company | $426.47 Million USD |
| Reuters | $426.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more